levofloxacin has been researched along with Tuberculosis, Drug-Resistant in 101 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (2.97) | 18.2507 |
2000's | 13 (12.87) | 29.6817 |
2010's | 59 (58.42) | 24.3611 |
2020's | 26 (25.74) | 2.80 |
Authors | Studies |
---|---|
Guo, H; Li, L; Liu, M; Lu, Y; Shen, W; Wang, B; Wang, M; Zhang, R; Zhang, T | 1 |
Chopra, S; Dusthackeer, VNA; Krishna, EV; Krishna, VS; Mahizhaveni, B; Makane, VB; Misra, S; Rode, HB; Shukla, M; Sriram, D | 1 |
Chopra, S; Choudhari, AS; Dusthackeer, VNA; Gaikwad, VR; Karale, UB; Krishna, EV; Krishna, VS; Mahizhaveni, B; Misra, S; Rode, HB; Sarkar, D; Shukla, M; Sriram, D | 1 |
Batt, SM; Besra, GS; Fu, L; Huang, H; Li, G; Lu, Y; Qin, R; Wang, B; Wang, P; Wang, Y; Wu, C | 1 |
Chopra, S; Dasgupta, A; Kaul, G; Kumar Sahoo, S; Maddipatla, S; Madhavi Yaddanapudi, V; Nageswara Rao Gajula, S; Naiyaz Ahmad, M; Nanduri, S; Sonti, R | 1 |
Blackman, A; Cáceres, T; Cachay, R; Gotuzzo, E; Maruri, F; Meza, E; Schwalb, A; Sterling, TR | 1 |
Leung, PKL; Ng, KKM; Yip, PCW | 1 |
Chen, X; Fu, L; Gao, T; Huo, F; Li, Q; Lu, Y; Pang, Y; Wang, B; Zhang, X | 1 |
Jiang, H; Li, X; Niu, Q; Xing, Z; Xu, J | 1 |
Dodd, PJ; Mafirakureva, N; McQuaid, CF; Seddon, JA | 1 |
Garcia-Prats, AJ; Hesseling, AC; Hoddinott, G; Purchase, SE; Reis, R; Reynolds, LJ; Seddon, JA; Wademan, DT | 1 |
Cachay, R; Diacon, AH; Gotuzzo, E; Horsburgh, CR; Kaur, P; Mitnick, CD; Phillips, PPJ; Schwalb, A; Sterling, TR; Ugarte-Gil, C; Wright, A | 1 |
Alarcón, MJ; Coronel, J; Cotrina, VV; Moore, DAJ; Puyén, ZM; Santos-Lázaro, D; Vigo, AN | 1 |
Gao, J; Gao, M; Li, L; Liu, F; Liu, Y; Pang, Y; Shu, W; Sun, Y; Xie, L; Zhang, L | 1 |
Hsiao, HC; Jou, R; Wu, SH; Xiao, YX | 1 |
Brankin, A; Colman, RE; Georghiou, SB; Seifert, M; Suresh, A; Uplekar, S; Walker, TM | 1 |
Ahn, JH; Cho, SN; Hahn, S; Jeon, D; Jhun, BW; Jo, KW; Kang, YA; Kim, DK; Kim, J; Kim, JS; Kim, K; Kim, S; Kim, SY; Kim, YR; Kwak, N; Lee, JK; Lee, JY; Lee, M; Lee, SH; Lee, T; Mok, J; Park, JS; Seok, KH; Shim, TS; Yim, D; Yim, JJ; Yoon, S | 1 |
An, Q; Lin, R; Wang, C; Wang, D; Yang, Q | 1 |
Ali, AM; Draper, HR; Fourie, B; Garcia-Prats, AJ; Hesseling, AC; Hughes, J; Nielsen, J; Radtke, KK; Savic, RM; Schaaf, HS; Solans, BP; van der Laan, L; Winckler, J | 1 |
Aung, KJM; Decroo, T; Kuaban, C; Noeske, J; Piubello, A; Rieder, HL; Van Deun, A | 1 |
Behr, MA; Benedetti, A; Britton, WJ; Dowdy, DW; Fox, GJ; Graham, SM; Marais, BJ; Marks, GB; Mason, P; Menzies, D; Nguyen, BH; Nguyen, CB; Nguyen, TA; Nguyen, VN; Tran, PT; Velen, K | 1 |
Erber, J; Rothe, K; Schmid, RM; Schneider, J; Spinner, CD; Tschaikowsky, T; Weidlich, S | 1 |
Ghazvini, K; Hashemy, SI; Hoffner, S; Jamedar, SA; Meshkat, Z; Sayadi, M; Soleimanpour, S; Zare, H | 1 |
Dong, L; Huo, F; Li, S; Li, Y; Ma, Y; Pang, Y; Shang, Y; Xue, Y | 1 |
E R, V; Keny, S; Lawande, D; Parrikar, A | 1 |
Baloch, AQ; Ghazal, A; Khanzada, FM; Mustafa, T; Qadir, M; Rizvi, AH; Tahseen, S | 1 |
Eather, G; Matigian, N; O'Connor, B; Wilson, M | 1 |
Alffenaar, JW; Bruchfeld, J; Davies Forsman, L; Eliasson, E; Hoffner, S; Hong, C; Hu, Y; Ke, R; Kuhlin, J; Niward, K; Paues, J; Schön, T; Simonsson, USH; Werngren, J; Xu, B; Zheng, R; Zheng, X | 1 |
Qiujing, F; Weiwei, W | 1 |
Davies, GR; Peloquin, CA | 1 |
Mamatha, HG; Shanthi, V | 1 |
Aono, A; Chikamatsu, K; Igarashi, Y; Mitarai, S; Takaki, A; Yamada, H; Yi, L | 1 |
Andres, S; Beckert, P; Heyckendorf, J; Hillemann, D; Kohl, TA; Köser, CU; Lange, C; Merker, M; Moradigaravand, D; Niemann, S; Olaru, ID; Parkhill, J; Peacock, SJ; Schleusener, V; Schön, T; Sturegård, E | 1 |
Denti, P; Dooley, KE; Draper, HR; Garcia-Prats, AJ; Hesseling, AC; McIlleron, HM; Savic, RM; Schaaf, HS; Thee, S; Wiesner, L; Winckler, J | 1 |
Bastos, ML; Bertolde, AI; Cosme, LB; Dalcolmo, MP; do Prado, TN; Fregona, G; Kritski, A; Maciel, ELN; Sanchez, MN; Trajman, A; Zandonade, E | 1 |
Bouton, TC; Butler, D; Diacon, AH; Dianis, N; Eisenach, K; Gandhi, NR; Gotuzzo, E; Horsburgh, CR; Hunt, KR; Lecca, L; Martel, B; Mitnick, CD; Moreno-Martinez, A; Patientia, RF; Peloquin, CA; Phillips, PPJ; Santillan, J; Seas, C; Vargas, D; von Groote-Bidlingmaier, F | 1 |
Behera, D; Kaur, P; Saini, A; Sethi, S; Yadav, R | 1 |
Burger, A; Draper, HR; Finlayson, H; Fourie, B; Garcia-Prats, AJ; Hesseling, AC; Schaaf, HS; Thee, S; Winckler, J | 1 |
Aktoğu Özkan, S; Biçmen, C; Çavuşoğlu, C; Eraç, B; Ermertcan, Ş; Hoşgör Limoncu, M; Yılmaz, FF | 1 |
Boulle, A; Fox, T; Khomo, N; Kock, Y; Leslie, J; Manning, K; Meintjes, G; Mudaly, V; Stewart, A; Tiffin, N; Wasserman, S; Zhao, Y | 1 |
Ahmad, N; Ahuja, SD; Akkerman, OW; Alffenaar, JC; Anderson, LF; Baghaei, P; Bang, D; Barry, PM; Bastos, ML; Behera, D; Benedetti, A; Bisson, GP; Boeree, MJ; Bonnet, M; Brode, SK; Brust, JCM; Cai, Y; Caumes, E; Cegielski, JP; Centis, R; Chan, ED; Chan, PC; Chang, KC; Charles, M; Cirule, A; D'Ambrosio, L; Dalcolmo, MP; de Vries, G; Dheda, K; Esmail, A; Flood, J; Fox, GJ; Fréchet-Jachym, M; Fregona, G; Gayoso, R; Gegia, M; Gler, MT; Gu, S; Guglielmetti, L; Holtz, TH; Hughes, J; Isaakidis, P; Jarlsberg, L; Kempker, RR; Keshavjee, S; Khan, FA; Kipiani, M; Koenig, SP; Koh, WJ; Kritski, A; Kuksa, L; Kvasnovsky, CL; Kwak, N; Lan, Z; Lange, C; Laniado-Laborín, R; Lee, M; Leimane, V; Leung, CC; Leung, EC; Li, PZ; Lowenthal, P; Maciel, EL; Marks, SM; Mase, S; Mbuagbaw, L; Menzies, D; Migliori, GB; Milanov, V; Miller, AC; Mitnick, CD; Modongo, C; Mohr, E; Monedero, I; Nahid, P; Ndjeka, N; O'Donnell, MR; Padayatchi, N; Palmero, D; Pape, JW; Podewils, LJ; Reynolds, I; Riekstina, V; Robert, J; Rodriguez, M; Schnippel, K; Seaworth, B; Seung, KJ; Shim, TS; Singla, R; Smith, SE; Sotgiu, G; Sukhbaatar, G; Tabarsi, P; Tiberi, S; Trajman, A; Trieu, L; Udwadia, ZF; van der Werf, TS; Veziris, N; Viiklepp, P; Vilbrun, SC; Walsh, K; Westenhouse, J; Yew, WW; Yim, JJ; Zetola, NM; Zignol, M | 1 |
Bantubani, N; Chotoo, S; Conradie, F; Enwerem, M; Ferreira, H; Hughes, J; Ismail, N; Maartens, G; Master, I; Meintjes, G; Mohr, E; Ndjeka, N; Padanilam, X; Romero, R; Schnippel, K; Singh, N; Te Riele, J; Variava, E | 1 |
Bendet, P; Deshpande, D; Gumbo, T; Heysell, SK; Koeuth, T; Lee, PS; Mpagama, SG; Pasipanodya, JG; Srivastava, S | 1 |
Ambrose, PG; Bendet, P; Bhavnani, SM; Deshpande, D; Gumbo, T; Heysell, SK; Koeuth, T; Lee, PS; Mpagama, SG; Pasipanodya, JG; Srivastava, S; Thwaites, G | 1 |
Alarcón Guizado, VA; Alarcon, E; Cornejo Garcia, JG; Heldal, E; Mendoza Ticona, A; Moore, DAJ | 1 |
De Koker, P; Draper, HR; Garcia-Prats, AJ; Hesseling, AC; Osman, M; Purchase, SE; Schaaf, HS; Seddon, JA | 1 |
Crook, AM; Demers, AM; Fairlie, L; Garcia-Prats, AJ; Gibb, DM; Hesseling, AC; Hoddinott, G; Martinson, N; Osman, M; Owen-Powell, E; Purchase, SE; Schaaf, HS; Seddon, JA; Thomason, MJ; Turkova, A | 1 |
Ahn, H; Ahn, JH; Cho, SN; Hahn, S; Jang, JY; Jeon, D; Jhun, BW; Jo, KW; Kang, YA; Kim, CK; Kim, DK; Kim, JS; Kim, SY; Kim, YR; Koh, WJ; Lee, JH; Lee, JY; Lee, M; Lee, SH; Lee, T; Mok, J; Park, JS; Shim, TS; Shin, S; Shin, SJ; Song, T; Won, HJ; Yim, JJ | 1 |
Alffenaar, JC; Ghimire, GR; Ghimire, S; Jongedijk, EM; Kosterink, JGW; Maharjan, B; Shrestha, B; Touw, DJ; van der Werf, TS | 1 |
Denti, P; Draper, HR; Garcia-Prats, AJ; Hesseling, AC; Osman, M; Purchase, SE; Schaaf, HS; Wiesner, L | 1 |
Alvarez-Cabrera, N; Blanc, L; Dartois, V; Dias-Freedman, I; Dietzold, J; Ho Liang, HP; Kaya, F; Kirschner, D; Linderman, J; Mina, M; O'Brien, P; Pienaar, E; Prideaux, B; Salgame, P; Sarathy, J; Savic, RM; Zimmerman, M | 1 |
Amanullah, F; Becerra, MC; Brooks, MB; Fuad, J; Hussain, H; Jaswal, M; Malik, AA; Peloquin, CA; Siddiqui, S; Yuen, CM | 1 |
Ahmed, S; Al-Shaer, MH; Alghamdi, WA; Alkabab, Y; Alsultan, A; An, G; Banu, S; Barbakadze, K; Cegielski, JP; Heysell, SK; Houpt, E; Kempker, RR; Kipiani, M; Mikiashvili, L; Peloquin, CA | 1 |
Ader, F; Collardeau-Frachon, S; Gillet, Y; Huguet, A; Ohlmann, C | 1 |
Abbara, A; Abubakar, I; Alexander, E; Booth, H; Bothamley, GH; Creer, DD; Davidson, JA; Harris, RJ; Kon, OM; Kunst, H; Lalor, MK; Lipman, MC; Loebinger, MR; Loutet, MG; Lozewicz, S; McHugh, TD; Milburn, HJ; Mohiyuddin, T; Palchaudhuri, P; Phillips, PPJ; Schmok, E; Stagg, HR; Taylor, L | 1 |
Ahmed, I; Hasan, R; Inayat, R; Jabeen, K | 1 |
Jiang, RH; Li, L; Xu, HB | 1 |
Davies, GR; Titarenko, AF; Ziganshina, LE | 1 |
Cataldi, AA; Di Giulio, AB; Imperiale, BR; Morcillo, NS; Zumárraga, MJ | 1 |
Chan Kim, K; Choi, JC; Choi, SB; Choi, WI; Heo, EY; Hwang, YI; Jang, SH; Jeon, K; Jung, KH; Kang, YA; Ki, YW; Kim, KU; Kim, SJ; Kim, YH; Koh, WJ; Kwon, YS; Lee, CH; Lee, J; Lee, JH; Lee, SH; Lee, YS; Ryu, YJ; Shim, TS; Um, S; Yim, JJ; Yoo, KH | 1 |
Schluger, NW | 1 |
Caleffi-Ferracioli, KR; Cardoso, RF; Maltempe, FG; Siqueira, VL | 1 |
Gratz, J; Heysell, SK; Houpt, ER; Kibiki, GS; Kumburu, H; Mpagama, SG; Ndusilo, N; Peloquin, CA; Stroup, S | 1 |
Behera, C; Krishna, K; Singh, HR | 1 |
Adler-Shohet, FC; Carson, M; Girma, H; Low, J; Singh, J | 1 |
Castel, S; Draper, HR; Garcia-Prats, AJ; Hesseling, AC; McIlleron, HM; Norman, J; Schaaf, HS; Thee, S; van der Merwe, PL; Wiesner, L | 1 |
Jeong, BH; Koh, WJ; Kwon, YS | 1 |
Alvarez, N; Araque, P; Mejía, GI; Peláez, C; Realpe, T; Robledo, J; Rouzaud, F; Zapata, E | 1 |
Bharti, H; Bhushan, B; Chander, R; Gupta, A; Kajal, NC; Ranga, V | 1 |
Bablishvili, N; Barth, AB; Blumberg, HM; Derendorf, H; Gogishvili, S; Guarner, J; Kempker, RR; Nikolaishvili, K; Peloquin, CA; Sabulua, I; Singh, RS; Tukvadze, N; Vashakidze, S | 1 |
Donald, PR; Garcia-Prats, AJ; Hesseling, AC; Schaaf, HS; Thee, S | 1 |
Alsultan, A; An, G; Peloquin, CA | 1 |
Ader, F; Bouaziz, A; Catho, G; Dumitriescu, O; Pedone, C; Perpoint, T; Reix, P; Ronnaux-Baron, AS; Sénéchal, A; Valour, F | 1 |
Huh, HJ; Jeon, K; Jeong, BH; Koh, WJ; Lee, H; Lee, NY; Park, HY | 1 |
Bamrah Morris, S; Brostrom, R; Chorba, T; Daley, CL; Fred, D; Gonzalez, D; Jereb, JA; Loeffler, AM; Martin, F; Mase, SR; Menon, LR; Peloquin, CA | 1 |
Bae, DW; Cho, SN; Dartois, V; Desta, KT; Eum, SY; Lee, SJ; Shin, SC | 1 |
Choi, JC; Choi, SB; Choi, WI; Heo, E; Hwang, YI; Jang, SH; Jeon, K; Jung, KH; Kang, YA; Kim, KC; Kim, KU; Kim, SJ; Kim, YH; Koh, WJ; Kwon, YS; Lee, CH; Lee, HK; Lee, JH; Lee, SH; Ryu, YJ; Shim, TS; Um, S; Yim, JJ; Yoo, KH | 1 |
Baboolal, SO; Garcia-Prats, AJ; Hesseling, AC; Mohamed, N; Schaaf, HS; Solomons, R; van der Laan, LE; van Toorn, R; Willemse, M | 1 |
Akkerman, OW; Alffenaar, JW; de Lange, WC; Ghimire, S; Kosterink, JG; Touw, DJ; van der Werf, TS; van Soolingen, D; Van't Boveneind-Vrubleuskaya, N; Wilffert, B | 1 |
Adebola, SO; Adedeji, TO; Adefuye, BO; Oladeji, SM; Sogebi, OA | 1 |
Ebers, A; Heysell, S; Kisonga, R; Lekule, I; Liu, J; Mpagama, S; Stroup, S | 1 |
Sterling, TR | 1 |
Chan, RC; Chang, KC; Yew, WW | 1 |
Chung, HS; Han, SK; Kim, DK; Kim, JY; Kim, YW; Lee, CH; Lee, CT; Lee, J; Lee, JH; Lee, SM; Yang, SC; Yim, JJ; Yoo, CG; Yoon, HI | 1 |
Bourdon, O; Chauny, JV; De Lauzanne, A; Doit, C; Géréral, T; Lorrot, M; Prot-Labarthe, S | 1 |
Dolovich, LR; Holbrook, A; Loeb, M; Papastavros, T; Whitehead, L | 1 |
Covi, M; Fabbri, LM; Ferrara, G; Franco, F; Meschiari, E; Richeldi, L; Vailati, P; Velluti, G | 1 |
Chen, L; Chen, QL; Yin, JJ | 1 |
Chan, CK; Chau, CH; Lee, J; Leung, CC; Tam, CM; Wong, PC; Yew, WW | 2 |
Li, SM; Xing, BC; Zheng, XM | 1 |
Squire, SB; Vizel, AA; Ziganshina, LE | 1 |
Hirano, A; Kawata, N; Kimura, G; Okada, C; Shibayama, T; Soda, R; Tada, A; Takahashi, K; Takahashi, S; Takeuchi, M | 1 |
Squire, SB; Ziganshina, LE | 1 |
Cohen, C; de Gouveia, L; du Plessis, M; Govender, N; Hoffmann, R; Klugman, KP; Meiring, S; Mpembe, R; Quan, V; Schrag, S; Smith, AM; von Gottberg, A; Whitelaw, A; Wolter, N | 1 |
Au, KF; Chau, CH; Lee, J; Yew, WW | 1 |
Berning, SE; Huitt, GA; Iseman, MD; Peloquin, CA | 1 |
Benson, CA; Chirgwin, KD; El-Sadr, WM; Matts, JP; Nelson, ET; Perlman, DC; Sepkowitz, KA; Telzak, EE | 1 |
Berning, SE; Cherry, TA; Iseman, MD | 1 |
Hoeppner, V; Marciniuk, D; Peloquin, CA; Reid, J | 1 |
Angkananukool, K; Pracharktam, R; Vibhagool, A | 1 |
11 review(s) available for levofloxacin and Tuberculosis, Drug-Resistant
Article | Year |
---|---|
Evaluation of genetic mutations associated with phenotypic resistance to fluoroquinolones, bedaquiline, and linezolid in clinical Mycobacterium tuberculosis: A systematic review and meta-analysis.
Topics: Antitubercular Agents; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Mycobacterium tuberculosis; Phenotype; Tuberculosis, Multidrug-Resistant | 2023 |
The Treatment of Tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Monitoring; Drug Therapy, Combination; Humans; Isoniazid; Levofloxacin; Rifampin; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2021 |
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Carbapenems; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Fluoroquinolones; Humans; Kanamycin; Levofloxacin; Linezolid; Moxifloxacin; Recurrence; Treatment Failure; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2018 |
Fluoroquinolones for treating tuberculosis (presumed drug-sensitive).
Topics: Antitubercular Agents; Ciprofloxacin; Drug Substitution; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Randomized Controlled Trials as Topic; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2013 |
Tuberculosis: clinical trials and new drug regimens.
Topics: Acetamides; Adamantane; Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Administration Schedule; Drug Design; Ethylenediamines; Female; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Male; Moxifloxacin; Nitroimidazoles; Oxazoles; Oxazolidinones; Spiro Compounds; Thiazines; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2014 |
Fluoroquinolones for the treatment of tuberculosis in children.
Topics: Age Factors; Antitubercular Agents; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Risk Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2015 |
[Children exposed to multidrug-resistant tuberculosis: How should we manage? Analysis of 46 child contacts and review of the literature].
Topics: Amikacin; Anti-Bacterial Agents; Child; Child, Preschool; Female; France; Humans; Infant; Latent Tuberculosis; Levofloxacin; Lost to Follow-Up; Male; Tuberculosis, Multidrug-Resistant | 2015 |
Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB.
Topics: Adult; Anti-Bacterial Agents; Antitubercular Agents; Child; Clinical Trials as Topic; Extensively Drug-Resistant Tuberculosis; Humans; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2016 |
Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis.
Topics: Antitubercular Agents; Aza Compounds; Bacterial Proteins; DNA Gyrase; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Genotype; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Sensitivity and Specificity; Tuberculosis, Multidrug-Resistant | 2010 |
Fluoroquinolones for treating tuberculosis.
Topics: Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Randomized Controlled Trials as Topic; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2005 |
Fluoroquinolones for treating tuberculosis.
Topics: Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Randomized Controlled Trials as Topic; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2008 |
12 trial(s) available for levofloxacin and Tuberculosis, Drug-Resistant
Article | Year |
---|---|
Factors associated with screening failure and study withdrawal in multidrug-resistant TB.
Topics: Antitubercular Agents; Humans; Levofloxacin; Mycobacterium tuberculosis; South Africa; Sputum; Tuberculosis, Multidrug-Resistant | 2022 |
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in So
Topics: Antitubercular Agents; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Male; Pyrazinamide; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2022 |
Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Incidence; Latent Tuberculosis; Levofloxacin; Male; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Vietnam; Young Adult | 2020 |
An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.
Topics: Antitubercular Agents; Clinical Protocols; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Research Design; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2017 |
Treatment outcomes for isoniazid-monoresistant tuberculosis in Peru, 2012-2014.
Topics: Adolescent; Adult; Child; Child, Preschool; Cross-Sectional Studies; Drug Therapy, Combination; Ethambutol; Female; Humans; Infant; Infant, Newborn; Isoniazid; Levofloxacin; Male; Middle Aged; Peru; Pyrazinamide; Retrospective Studies; Rifampin; Sex Factors; Time Factors; Tuberculosis, Multidrug-Resistant | 2018 |
Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP).
Topics: Age Factors; Antitubercular Agents; Child, Preschool; Clinical Trials, Phase III as Topic; Contact Tracing; Cost-Benefit Analysis; Drug Administration Schedule; Drug Costs; Female; Housing; Humans; Infant; Levofloxacin; Male; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; South Africa; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2018 |
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, m
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Equivalence Trials as Topic; Female; Humans; Levofloxacin; Linezolid; Male; Middle Aged; Multicenter Studies as Topic; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Republic of Korea; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2019 |
Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure.
Topics: Antitubercular Agents; Biological Availability; Child, Preschool; Female; Humans; Infant; Levofloxacin; Male; Placebos; Tablets; Tuberculosis, Multidrug-Resistant | 2019 |
Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Aza Compounds; Fluoroquinolones; Humans; Levofloxacin; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Republic of Korea; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2013 |
Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Female; Humans; Levofloxacin; Male; Middle Aged; Tuberculosis, Multidrug-Resistant; Young Adult | 2015 |
Choice between Levofloxacin and Moxifloxacin and Multidrug-Resistant Tuberculosis Treatment Outcomes.
Topics: Adult; Anti-Bacterial Agents; Female; Fluoroquinolones; Humans; Levofloxacin; Logistic Models; Male; Middle Aged; Moxifloxacin; Multivariate Analysis; Proportional Hazards Models; Prospective Studies; Republic of Korea; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2016 |
[Short-term effect of treatment protocol utilizing levofloxacin, pasiniazide and M. Vaccae on multi- drug resistant pulmonary tuberculosis].
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Aminosalicylic Acid; Aminosalicylic Acids; Clinical Protocols; Drug Therapy, Combination; Female; Humans; Isoniazid; Levofloxacin; Male; Middle Aged; Ofloxacin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2004 |
78 other study(ies) available for levofloxacin and Tuberculosis, Drug-Resistant
Article | Year |
---|---|
Synthesis, antimycobacterial and antibacterial activity of fluoroquinolone derivatives containing an 3-alkoxyimino-4-(cyclopropylanimo)methylpyrrolidine moiety.
Topics: Anti-Bacterial Agents; Dose-Response Relationship, Drug; Enterococcus; Fluoroquinolones; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrrolidines; Structure-Activity Relationship; Tuberculosis, Multidrug-Resistant | 2015 |
Synthesis and evaluation of α-aminoacyl amides as antitubercular agents effective on drug resistant tuberculosis.
Topics: Amides; Animals; Antitubercular Agents; Cell Line; Chemistry, Pharmaceutical; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Tuberculosis, Multidrug-Resistant | 2019 |
Synthesis and biological evaluation of 2,4,5-trisubstituted thiazoles as antituberculosis agents effective against drug-resistant tuberculosis.
Topics: Antitubercular Agents; Dose-Response Relationship, Drug; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Thiazoles; Tuberculosis, Multidrug-Resistant | 2019 |
Identification of thiophene-benzenesulfonamide derivatives for the treatment of multidrug-resistant tuberculosis.
Topics: Animals; Antitubercular Agents; Benzenesulfonamides; Mice; Microbial Sensitivity Tests; Molecular Docking Simulation; Mycobacterium tuberculosis; Structure-Activity Relationship; Sulfonamides; Thiophenes; Tuberculosis, Multidrug-Resistant | 2022 |
Identification of nitrofuranylchalcone tethered benzoxazole-2-amines as potent inhibitors of drug resistant Mycobacterium tuberculosis demonstrating bactericidal efficacy.
Topics: Amines; Animals; Antitubercular Agents; Benzoxazoles; Chlorocebus aethiops; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitrofurans; Tuberculosis; Tuberculosis, Multidrug-Resistant; Vero Cells | 2022 |
Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Peru; Pharmaceutical Preparations; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2021 |
Prevalences of levofloxacin resistance and
Topics: Amidohydrolases; Antitubercular Agents; Hong Kong; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Prevalence; Tuberculosis, Multidrug-Resistant | 2021 |
Molecular Characteristic of Both Levofloxacin and Moxifloxacin Resistance in
Topics: Anti-Bacterial Agents; Antitubercular Agents; DNA Gyrase; Genes, Bacterial; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Tuberculosis, Multidrug-Resistant | 2022 |
Intracellular Activity of Poly (DL-Lactide-co-Glycolide) Nanoparticles Encapsulated with Prothionamide, Pyrazinamide, Levofloxacin, Linezolid, or Ethambutol on Multidrug-Resistant
Topics: Anti-Bacterial Agents; Antitubercular Agents; Ethambutol; Humans; Levofloxacin; Linezolid; Mycobacterium tuberculosis; Nanoparticles; Polylactic Acid-Polyglycolic Acid Copolymer; Prothionamide; Pyrazinamide; Reactive Oxygen Species; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2023 |
The global impact of household contact management for children on multidrug-resistant and rifampicin-resistant tuberculosis cases, deaths, and health-system costs in 2019: a modelling study.
Topics: Adult; Antitubercular Agents; Child; HIV Infections; Humans; Levofloxacin; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2022 |
Practical and psychosocial challenges faced by caregivers influence the acceptability of multidrug-resistant tuberculosis preventive therapy for young children.
Topics: Antitubercular Agents; Caregivers; Child, Preschool; Humans; Levofloxacin; Mycobacterium tuberculosis; Tuberculosis, Multidrug-Resistant | 2022 |
Evaluation of the broth microdilution plate methodology for susceptibility testing of Mycobacterium tuberculosis in Peru.
Topics: Antitubercular Agents; Ethambutol; Ethionamide; Humans; Isoniazid; Kanamycin; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Peru; Rifampin; Tuberculosis, Lymph Node; Tuberculosis, Multidrug-Resistant | 2022 |
Development and Validation of a Nomogram for Prediction of QT Interval Prolongation in Patients Administered Bedaquiline-Containing Regimens in China: a Modeling Study.
Topics: Antitubercular Agents; Clofazimine; Creatinine; Diarylquinolines; Humans; Levofloxacin; Long QT Syndrome; Moxifloxacin; Nomograms; Tuberculosis, Multidrug-Resistant | 2022 |
Development and Assessment of a Novel Whole-Gene-Based Targeted Next-Generation Sequencing Assay for Detecting the Susceptibility of Mycobacterium tuberculosis to 14 Drugs.
Topics: Amikacin; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Ethambutol; High-Throughput Nucleotide Sequencing; Humans; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Rifampin; Tuberculosis, Multidrug-Resistant | 2022 |
In silico evaluation of WHO-endorsed molecular methods to detect drug resistant tuberculosis.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Genotype; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Multidrug-Resistant; World Health Organization | 2022 |
QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Clofazimine; Electrocardiography; Humans; Levofloxacin; Rifampin; South Africa; Tuberculosis, Multidrug-Resistant | 2023 |
Gatifloxacin is superior to levofloxacin and moxifloxacin in shorter treatment regimens for multidrug-resistant TB.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Bangladesh; Cameroon; Child; Drug Administration Schedule; Female; Gatifloxacin; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Niger; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2019 |
Successful bedaquiline-containing antimycobacterial treatment in post-traumatic skin and soft-tissue infection by Mycobacterium fortuitum complex: a case report.
Topics: Amikacin; Antitubercular Agents; Diarylquinolines; Drug Resistance, Bacterial; Female; Humans; Imipenem; Levofloxacin; Macrolides; Mycobacterium fortuitum; Mycobacterium Infections, Nontuberculous; Skin; Skin Diseases, Bacterial; Soft Tissue Infections; Soft Tissue Injuries; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Vietnam; Young Adult | 2020 |
Genotypic and phenotypic characterization of Mycobacterium tuberculosis resistance against fluoroquinolones in the northeast of Iran.
Topics: Antitubercular Agents; Codon; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Genotype; Humans; Iran; Levofloxacin; Male; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Ofloxacin; Tuberculosis, Multidrug-Resistant | 2020 |
Specific gyrA Gene Mutations Correlate with High Prevalence of Discordant Levofloxacin Resistance in Mycobacterium tuberculosis Isolates from Beijing, China.
Topics: Antitubercular Agents; Beijing; DNA Gyrase; DNA, Bacterial; Drug Resistance, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Prevalence; Retrospective Studies; Sequence Analysis, DNA; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2020 |
Gitelman-like syndrome: A rare complication of using aminoglycosides in tuberculosis - A case report.
Topics: Alkalosis; Antitubercular Agents; Capreomycin; Clofazimine; Cycloserine; Deprescriptions; Ethionamide; Gitelman Syndrome; Humans; Hypocalcemia; Hypokalemia; Levofloxacin; Linezolid; Male; Middle Aged; Pyrazinamide; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Water-Electrolyte Imbalance | 2020 |
Isoniazid resistance profile and associated levofloxacin and pyrazinamide resistance in rifampicin resistant and sensitive isolates/from pulmonary and extrapulmonary tuberculosis patients in Pakistan: A laboratory based surveillance study 2015-19.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Drug Resistance, Bacterial; Epidemiological Monitoring; Female; Genotype; Humans; Infant; Isoniazid; Laboratories; Levofloxacin; Male; Microbial Sensitivity Tests; Pakistan; Phenotype; Pyrazinamide; Retrospective Studies; Rifampin; Tuberculosis, Multidrug-Resistant; Young Adult | 2020 |
Management of isoniazid-monoresistant tuberculosis (Hr-TB) in Queensland, Australia: a retrospective case series.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Australia; Child; Child, Preschool; Drug Therapy, Combination; Ethambutol; Ethinyl Estradiol-Norgestrel Combination; Female; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Male; Middle Aged; Pyrazinamide; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2020 |
Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China.
Topics: Antitubercular Agents; China; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pharmaceutical Preparations; Prospective Studies; Tuberculosis, Multidrug-Resistant | 2021 |
Efficacy of moxifloxacin combined with levofloxacin in the treatment of drug-resistant tuberculosis.
Topics: Adult; Antibiotics, Antitubercular; Case-Control Studies; Drug Therapy, Combination; Female; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Random Allocation; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2020 |
Baseline resistance and cross-resistance among fluoroquinolones in multidrug-resistant Mycobacterium tuberculosis isolates at a national reference laboratory in India.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Humans; India; Levofloxacin; Male; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Prevalence; Prospective Studies; Tuberculosis, Multidrug-Resistant; Young Adult | 2018 |
Laboratory evaluation of the Anyplex™ II MTB/MDR and MTB/XDR tests based on multiplex real-time PCR and melting-temperature analysis to identify Mycobacterium tuberculosis and drug resistance.
Topics: Antitubercular Agents; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Kanamycin; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Reagent Kits, Diagnostic; Real-Time Polymerase Chain Reaction; Rifampin; Sensitivity and Specificity; Seoul; Sequence Analysis, DNA; Tuberculosis, Multidrug-Resistant | 2017 |
What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis.
Topics: Antitubercular Agents; Bacterial Typing Techniques; Cohort Studies; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Genome, Bacterial; Genotype; Humans; Kanamycin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Phenotype; Rifampin; Tuberculosis, Multidrug-Resistant; Whole Genome Sequencing | 2018 |
Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Area Under Curve; Child; Child, Preschool; Coinfection; Drug Administration Schedule; Drug Dosage Calculations; Female; HIV; HIV Infections; Humans; Infant; Levofloxacin; Male; Models, Statistical; Mycobacterium tuberculosis; Prospective Studies; South Africa; Tablets; Tuberculosis, Multidrug-Resistant | 2018 |
Treatment outcomes of MDR-tuberculosis patients in Brazil: a retrospective cohort analysis.
Topics: Adult; Antitubercular Agents; Brazil; Cohort Studies; Female; Humans; Levofloxacin; Male; Middle Aged; Recurrence; Retrospective Studies; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2017 |
Diagnostic accuracy of GenoType
Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Humans; India; Kanamycin; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Sensitivity and Specificity; Sequence Analysis, DNA; Tuberculosis, Multidrug-Resistant | 2018 |
Clinical and Cardiac Safety of Long-term Levofloxacin in Children Treated for Multidrug-resistant Tuberculosis.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Female; Heart; Humans; Levofloxacin; Male; Prospective Studies; South Africa; Time Factors; Tuberculosis, Multidrug-Resistant | 2018 |
In vitro effects of ciprofloxacin, levofloxacin and moxifloxacin on Mycobacterium tuberculosis isolates.
Topics: Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Tuberculosis; Tuberculosis, Multidrug-Resistant; Turkey | 2018 |
Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.
Topics: Adult; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethionamide; Female; HIV; HIV Infections; Humans; Isoniazid; Isoxazoles; Levofloxacin; Male; Mycobacterium tuberculosis; Oxazolidinones; Pyrazinamide; Retrospective Studies; South Africa; Survival Analysis; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2019 |
High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Resistance, Bacterial; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Female; Fluoroquinolones; HIV Infections; Humans; Levofloxacin; Linezolid; Male; Middle Aged; Poisson Distribution; South Africa; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2018 |
Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.
Topics: Antitubercular Agents; Ethionamide; Humans; Isoniazid; Levofloxacin; Monte Carlo Method; Mutation; Sputum; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2018 |
Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.
Topics: Algorithms; Antitubercular Agents; Artificial Intelligence; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Levofloxacin; Microbial Sensitivity Tests; Monte Carlo Method; Mycobacterium tuberculosis; Sputum; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2018 |
Acceptability of a Novel Levofloxacin Dispersible Tablet Formulation in Young Children Exposed to Multidrug-resistant Tuberculosis.
Topics: Antitubercular Agents; Child, Preschool; Drug Compounding; Female; Humans; Infant; Levofloxacin; Male; South Africa; Tablets; Tuberculosis, Multidrug-Resistant | 2019 |
Levofloxacin pharmacokinetics, pharmacodynamics and outcome in multidrug-resistant tuberculosis patients.
Topics: Humans; Levofloxacin; Prospective Studies; Tuberculosis, Multidrug-Resistant | 2019 |
Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations.
Topics: Animals; Antitubercular Agents; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Rabbits; Tandem Mass Spectrometry; Tuberculosis, Multidrug-Resistant | 2019 |
Pharmacokinetics of Levofloxacin in Children Treated for Exposure to Drug-Resistant Tuberculosis.
Topics: Antitubercular Agents; Humans; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pakistan; Tuberculosis, Multidrug-Resistant | 2019 |
Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Moxifloxacin; Ofloxacin; Retrospective Studies; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2019 |
Drug-Induced Fulminant Hepatitis in a Child Treated for Latent Multidrug-Resistant Tuberculosis With Dual Therapy Combining Pyrazinamide and Levofloxacin.
Topics: Antitubercular Agents; Child; Drug Therapy, Combination; Humans; Latent Tuberculosis; Levofloxacin; Male; Massive Hepatic Necrosis; Pyrazinamide; Tuberculosis, Multidrug-Resistant | 2019 |
Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Duration of Therapy; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Logistic Models; London; Male; Middle Aged; Practice Guidelines as Topic; Pyrazinamide; Recurrence; Retrospective Studies; Rifampin; Treatment Failure; Tuberculosis, Multidrug-Resistant; World Health Organization; Young Adult | 2019 |
Susceptibility testing of extensively drug-resistant and pre-extensively drug-resistant Mycobacterium tuberculosis against levofloxacin, linezolid, and amoxicillin-clavulanate.
Topics: Acetamides; Amoxicillin-Potassium Clavulanate Combination; Antitubercular Agents; Extensively Drug-Resistant Tuberculosis; Humans; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin; Oxazolidinones; Pakistan; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2013 |
Comparative roles of moxifloxacin and levofloxacin in the treatment of pulmonary multidrug-resistant tuberculosis: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Aza Compounds; China; Drug-Related Side Effects and Adverse Reactions; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Recurrence; Retrospective Studies; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2013 |
Molecular and phenotypic characterisation of Mycobacterium tuberculosis resistant to anti-tuberculosis drugs.
Topics: Antitubercular Agents; Argentina; Bacterial Typing Techniques; DNA, Bacterial; Drug Resistance, Bacterial; Extensively Drug-Resistant Tuberculosis; Genotype; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Rifampin; Sequence Analysis, DNA; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2013 |
Fluoroquinolones in the treatment of tuberculosis: which is best?
Topics: Aza Compounds; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Quinolines; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2013 |
Fast detection of drug interaction in Mycobacterium tuberculosis by a checkerboard resazurin method.
Topics: Antitubercular Agents; Drug Combinations; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Synergism; Ethambutol; Humans; Indicators and Reagents; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Microbial Viability; Mycobacterium tuberculosis; Oxazines; Tuberculosis; Tuberculosis, Multidrug-Resistant; Xanthenes | 2013 |
Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
Topics: Adolescent; Adult; Amikacin; Antitubercular Agents; Cycloserine; Ethionamide; Female; Fluoroquinolones; Humans; Kanamycin; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Sputum; Tanzania; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2014 |
Antitubercular drug-induced violent suicide of a hospitalised patient.
Topics: Antitubercular Agents; Cycloserine; Drug Therapy, Combination; Ethambutol; Heart Injuries; Hospitalization; Humans; India; Levofloxacin; Male; Psychoses, Substance-Induced; Self-Injurious Behavior; Suicide; Tuberculosis, Multidrug-Resistant; Violence; Wounds, Stab; Young Adult | 2014 |
Management of latent tuberculosis infection in child contacts of multidrug-resistant tuberculosis.
Topics: Adolescent; Antibiotic Prophylaxis; Antitubercular Agents; Child; Contact Tracing; Humans; Latent Tuberculosis; Levofloxacin; Pyrazinamide; Retrospective Studies; Tuberculosis, Multidrug-Resistant | 2014 |
Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Female; Humans; Infant; Levofloxacin; Male; Ofloxacin; Prospective Studies; Tuberculosis, Multidrug-Resistant | 2014 |
The structural modeling of the interaction between levofloxacin and the Mycobacterium tuberculosis gyrase catalytic site sheds light on the mechanisms of fluoroquinolones resistant tuberculosis in Colombian clinical isolates.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Bacterial Proteins; Catalytic Domain; Colombia; Crystallography, X-Ray; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Female; Humans; Levofloxacin; Male; Molecular Docking Simulation; Mutation, Missense; Mycobacterium tuberculosis; Tuberculosis, Multidrug-Resistant | 2014 |
Profile of adverse drug reactions in drug resistant tuberculosis from Punjab.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Arthralgia; Ataxia; Chemical and Drug Induced Liver Injury; Child; Cycloserine; Drug Eruptions; Drug Therapy, Combination; Ethambutol; Ethionamide; Female; Gastrointestinal Diseases; Hearing Loss; Humans; Hypothyroidism; India; Kanamycin; Levofloxacin; Male; Middle Aged; Peripheral Nervous System Diseases; Psychoses, Substance-Induced; Pyrazinamide; Severity of Illness Index; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Vision Disorders; Young Adult | 2014 |
Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Area Under Curve; Brazil; Humans; Levofloxacin; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Monte Carlo Method; Mycobacterium tuberculosis; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2015 |
Treatment Outcomes with Fluoroquinolone-Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Recurrence; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2016 |
Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Drug Monitoring; Female; Humans; Infant; Latent Tuberculosis; Levofloxacin; Male; Microbial Sensitivity Tests; Micronesia; Mycobacterium tuberculosis; Tuberculosis, Multidrug-Resistant | 2016 |
Development and validation of LC-ESI-MS/MS method for analysis of moxifloxacin and levofloxacin in serum of multidrug-resistant tuberculosis patients: Potential application as therapeutic drug monitoring tool in medical diagnosis.
Topics: Antitubercular Agents; Chromatography, High Pressure Liquid; Drug Monitoring; Fluoroquinolones; Humans; Levofloxacin; Limit of Detection; Moxifloxacin; Tandem Mass Spectrometry; Tuberculosis, Multidrug-Resistant | 2016 |
Probable Levofloxacin-associated Secondary Intracranial Hypertension in a Child With Multidrug-resistant Tuberculosis.
Topics: Anti-Bacterial Agents; Child; Female; Humans; Intracranial Hypertension; Levofloxacin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2016 |
Clinical predictors of aminoglycoside-induced ototoxicity in drug-resistant Tuberculosis patients on intensive therapy.
Topics: Adult; Age Factors; Aminoglycosides; Antitubercular Agents; Audiometry, Pure-Tone; Body Mass Index; Coinfection; Comorbidity; Cycloserine; Diabetes Mellitus; Female; Hearing Loss; HIV Infections; Humans; Kanamycin; Levofloxacin; Male; Middle Aged; Nigeria; Prospective Studies; Prothionamide; Pyrazinamide; Risk Factors; Time Factors; Tuberculosis, Multidrug-Resistant; Young Adult | 2017 |
Determination of plasma concentrations of levofloxacin by high performance liquid chromatography for use at a multidrug-resistant tuberculosis hospital in Tanzania.
Topics: Adult; Calibration; Chromatography, High Pressure Liquid; Female; Hospitals; Humans; Levofloxacin; Male; Regression Analysis; Reproducibility of Results; Tanzania; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2017 |
Fluoroquinolones for the treatment and prevention of multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2016 |
Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes.
Topics: Adult; Antitubercular Agents; Aza Compounds; Case-Control Studies; Chi-Square Distribution; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Female; Fluoroquinolones; Humans; Levofloxacin; Logistic Models; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Odds Ratio; Ofloxacin; Quinolines; Recurrence; Remission Induction; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2011 |
Treatment of tuberculosis with levofloxacin or moxifloxacin: report of 6 pediatric cases.
Topics: Adolescent; Antitubercular Agents; Aza Compounds; Child; Child, Preschool; Female; Fluoroquinolones; France; Hospitals, University; Humans; Infant; Levofloxacin; Male; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2012 |
Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis.
Topics: Adolescent; Adult; Anti-Infective Agents; Antitubercular Agents; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pyrazinamide; Tuberculosis, Multidrug-Resistant | 2002 |
Clinical use of Levofloxacin in the long-term treatment of drug resistant tuberculosis.
Topics: Adult; Aged; Anti-Infective Agents; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Mycobacterium; Ofloxacin; Tuberculosis, Female Genital; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2002 |
[A study on the clinical efficacy of a combination regimen with levofloxacin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis].
Topics: Adolescent; Adult; Antitubercular Agents; Capreomycin; Drug Therapy, Combination; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Pyrazinamide; Rifampin; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2003 |
Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong.
Topics: Anti-Infective Agents; Female; Hong Kong; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2003 |
[In vitro antituberculous activity of ofloxacin and levofloxacin against multidrug-resistant tuberculosis and clinical outcomes].
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Drug Resistance, Multiple, Bacterial; Female; Humans; Levofloxacin; Male; Middle Aged; Mycobacterium tuberculosis; Ofloxacin; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2006 |
Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study.
Topics: Adolescent; Anti-Bacterial Agents; Antitubercular Agents; Child; Child, Preschool; Cross Infection; Cross-Sectional Studies; Drug Resistance, Bacterial; Female; Humans; Infant; Levofloxacin; Male; Ofloxacin; Pneumococcal Infections; Population Surveillance; Rifampin; Risk Factors; South Africa; Statistics, Nonparametric; Streptococcus pneumoniae; Tuberculosis, Multidrug-Resistant; World Health Organization | 2008 |
Levofloxacin in the treatment of drug-resistant tuberculosis.
Topics: Aged; Anti-Infective Agents; Antitubercular Agents; Drug Therapy, Combination; Follow-Up Studies; Humans; Levofloxacin; Male; Ofloxacin; Radiography; Tuberculosis, Multidrug-Resistant | 1997 |
Levofloxacin for drug-resistant Mycobacterium tuberculosis.
Topics: Adult; Anti-Infective Agents; Drug Administration Schedule; Humans; Levofloxacin; Mycobacterium tuberculosis; Ofloxacin; Tuberculosis, Multidrug-Resistant | 1998 |
Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Hea
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antitubercular Agents; Chi-Square Distribution; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; Levofloxacin; Logistic Models; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Pilot Projects; Prospective Studies; Risk Factors; Survival Analysis; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; United States | 1999 |
Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens.
Topics: Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Female; Hong Kong; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Mycobacterium tuberculosis; Ofloxacin; Recurrence; Retrospective Studies; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2000 |
Novel treatment of meningitis caused by multidrug-resistant Mycobacterium tuberculosis with intrathecal levofloxacin and amikacin: case report.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Drug Therapy, Combination; Humans; Injections, Spinal; Levofloxacin; Male; Mycobacterium tuberculosis; Ofloxacin; Tuberculosis, Meningeal; Tuberculosis, Multidrug-Resistant | 2001 |
Pharmacokinetics of antituberculosis medications delivered via percutaneous gastrojejunostomy tube.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Female; Gastrostomy; Humans; Jejunostomy; Levofloxacin; Ofloxacin; Rifampin; Saskatchewan; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2002 |
In vitro susceptibility testing of levofloxacin and ofloxacin by microtiter plate Alamar blue against multidrug and non multidrug resistant Mycobacterium tuberculosis in Thailand.
Topics: Coloring Agents; Culture Media; Drug Resistance, Multiple, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin; Oxazines; Sensitivity and Specificity; Tuberculosis, Multidrug-Resistant; Xanthenes | 2001 |